Vectura, the respiratory inhaler firm, reduced losses for the year, drove revenues higher and said it is on track for annual cost-savings of approximately £6m. Loss after tax reduced to £8.8m for the year ended 31 March 2011 from a loss of £10.2m in 2010. Revenue increased to £42.9m from £40.1m. Vectura said it expects several major catalysts in the near future including the Novartis' release of more NVA237 Phase III data and a file for regulatory approval in 2011, with launches expected in 2012. "The QVA149 Phase III trials are ongoing and Novartis expects the first product launches in 2013. We also anticipate further progress on VR315 in Europe," Vectura explained. Licensing activities will continue across all our areas including products, technologies and our broader intellectual property portfolio." Cash reserves rose to £10.3m from £74.4m at March 31 2011.